ArticleThe oncologist2026

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Rosalba Torrisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.